Bio-Thera Solutions (688177.SH): Ustekinumab injection receives positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency.

Bio-Thera Solutions (688177.SH) announced that the company has recently received a notification from the European Medicines Agency (EMA) that Usymro (BAT2206, ustekinumab injection) has received a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP). CHMP has recommended that the European Commission (EC) approve the marketing of Usymro for the treatment of moderate to severe plaque psoriasis (PsO) and active psoriatic arthritis (PsA) in adults and children, as well as moderate to severe active Crohn's disease (CD).